Global Dry Eye Syndrome Market is projected to be valued $5 Billion by 2024; with a CAGR of 6.8% from 2017 to 2025. Dry eye occurs whenever the eye does not produce enough tears or tears evaporate too quickly. This can happen due to contact lens use, allergies, pregnancy, vitamin A deficiency, LASIK surgery, tobacco smoke exposure and certain medications such as antihistamines, some blood pressure medication, hormone replacement therapy, and antidepressants. Dry Eye Syndrome is chronic disease condition for which NEI-supported researchers are studying the underlying causes of dry eye to better understand the disease and to develop novel treatments.
Growing prevalence of dry eye syndrome among population and increasing number of life style disease are the factors supporting the growth of the dry eye syndrome market. Moreover, government initiative and increase in the number of research and development also fuel the growth of market. The major restraints are expiry of patent and self- directed medication. Technological advancement would provide market opportunities in the coming years.
The global Dry Eye Syndrome market is segmented on the basis of type, treatment type, and geography. On the basis of type the market is segmented into evaporative dry eye and aqueous dry eye. Treatment type is further segmented into nutritional supplement, serum eye drops, lubricant eye drops (oily tear eye drops, ointments and preservative-free drops) and anti-inflammatory drugs (Tetracyclines and Corticosteroids).
By geography the market is segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW). The U.S., Canada and Mexico are covered under North America wherein Europe covers U.K., Germany, France, and others. Asia-Pacific covers India, China, Japan and others. RoW covers South America, Middle East and Africa.
Major companies operating in the global Dry Eye Syndrome market are Santen Pharmaceutical, Alcon (a wholly-owned subsidiary of Novartis), Shire/SAR code Bioscience, Allergan, EyegatePharma, Can-FiteBiopharma, Novartis, and Otsuka Holdings, among others.
The key takeaways from the report
Scope of Dry Eye Syndrome Market
Treatment Type Segments